Literature DB >> 22919028

Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.

Shinobu Matsuura1, Yukiko Komeno, Kristen E Stevenson, Joseph R Biggs, Kentson Lam, Tingdong Tang, Miao-Chia Lo, Xiuli Cong, Ming Yan, Donna S Neuberg, Dong-Er Zhang.   

Abstract

Mutations of RUNX1 are detected in patients with myelodysplastic syndrome (MDS). In particular, C-terminal truncation mutations lack a transcription regulatory domain and have increased DNA binding through the runt homology domain. The expression of the runt homology domain, RUNX1(41-214), in mouse hematopoietic cells induced progression to MDS and acute myeloid leukemia. Analysis of premyelodysplastic animals found expansion of c-Kit(+)Sca-1(+)Lin(-) cells and skewed differentiation to myeloid at the expense of the lymphoid lineage. These abnormalities correlate with the phenotype of Runx1-deficient animals, as expected given the reported dominant-negative role of C-terminal mutations over the full-length RUNX1. However, MDS is not observed in Runx1-deficient animals. Gene expression profiling found that RUNX1(41-214) c-Kit(+)Sca-1(+)Lin(-) cells have an overlapping yet distinct gene expression profile from Runx1-deficient animals. Moreover, an unexpected parallel was observed between the hematopoietic phenotype of RUNX1(41-214) and aged animals. Genes deregulated in RUNX1(41-214), but not in Runx1-deficient animals, were inversely correlated with the aging gene signature of HSCs, suggesting that disruption of the expression of genes related to normal aging by RUNX1 mutations contributes to development of MDS. The data presented here provide insights into the mechanisms of development of MDS in HSCs by C-terminal mutations of RUNX1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22919028      PMCID: PMC3496957          DOI: 10.1182/blood-2012-01-404533

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Cell intrinsic alterations underlie hematopoietic stem cell aging.

Authors:  Derrick J Rossi; David Bryder; Jacob M Zahn; Henrik Ahlenius; Rebecca Sonu; Amy J Wagers; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

2.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

3.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.

Authors:  Q Wang; T Stacy; M Binder; M Marin-Padilla; A H Sharpe; N A Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  The aging of hematopoietic stem cells.

Authors:  S J Morrison; A M Wandycz; K Akashi; A Globerson; I L Weissman
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

5.  Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.

Authors:  Joseph D Growney; Hirokazu Shigematsu; Zhe Li; Benjamin H Lee; Jennifer Adelsperger; Rebecca Rowan; David P Curley; Jeffery L Kutok; Koichi Akashi; Ifor R Williams; Nancy A Speck; D Gary Gilliland
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.

Authors:  M Osato; N Asou; E Abdalla; K Hoshino; H Yamasaki; T Okubo; H Suzushima; K Takatsuki; T Kanno; K Shigesada; Y Ito
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

8.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

9.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Authors:  Alexander Sternberg; Sally Killick; Tim Littlewood; Chris Hatton; Andy Peniket; Thomas Seidl; Shamit Soneji; Joanne Leach; David Bowen; Claire Chapman; Graham Standen; Edwin Massey; Lisa Robinson; Bipin Vadher; Richard Kaczmarski; Riaz Janmohammed; Kim Clipsham; Andrew Carr; Paresh Vyas
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

10.  Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.

Authors:  Guibin Chen; Weihua Zeng; Akira Miyazato; Eric Billings; Jaroslaw P Maciejewski; Sachiko Kajigaya; Elaine M Sloand; Neal S Young
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

View more
  10 in total

1.  In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Authors:  Jason H Mendler; Kati Maharry; Heiko Becker; Ann-Kathrin Eisfeld; Leigha Senter; Krzysztof Mrózek; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Michael A Caligiuri; Rebecca B Klisovic; Joseph O Moore; Thomas H Carter; Guido Marcucci; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

2.  Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors.

Authors:  S Rodriguez-Perales; R Torres-Ruiz; J Suela; F Acquadro; M C Martin; E Yebra; J C Ramirez; S Alvarez; J C Cigudosa
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

3.  A two-stage approach for combining gene expression and mutation with clinical data improves survival prediction in myelodysplastic syndromes and ovarian cancer.

Authors:  Yan Li; Xinyan Zhang; Tomi Akinyemiju; Akinyemi I Ojesina; Jeff M Szychowski; Nianjun Liu; Bo Xu; Nengjun Yi
Journal:  J Bioinform Genom       Date:  2016-09-15

4.  Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.

Authors:  Yukiko Komeno; Ming Yan; Shinobu Matsuura; Kentson Lam; Miao-Chia Lo; Yi-Jou Huang; Daniel G Tenen; James R Downing; Dong-Er Zhang
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

5.  Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice.

Authors:  Kentson Lam; Alexander Muselman; Randal Du; Yuka Harada; Amanda G Scholl; Ming Yan; Shinobu Matsuura; Stephanie Weng; Hironori Harada; Dong-Er Zhang
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

6.  RUNX1-205, a novel splice variant of the human RUNX1 gene, has blockage effect on mesoderm-hemogenesis transition and promotion effect during the late stage of hematopoiesis.

Authors:  Wencui Sun; Jiahui Zeng; Jing Chang; Yuan Xue; Yonggang Zhang; Xu Pan; Ya Zhou; Mowen Lai; Guohui Bian; Qiongxiu Zhou; Jiaxing Liu; Bo Chen; Feng Ma
Journal:  J Mol Cell Biol       Date:  2020-06-11       Impact factor: 6.216

7.  Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.

Authors:  Kiyoko Yamamoto; Shinobu Tsuzuki; Yosuke Minami; Yukiya Yamamoto; Akihiro Abe; Koichi Ohshima; Masao Seto; Tomoki Naoe
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

8.  Loss of RUNX1 function results in enhanced granulocyte-colony-stimulating factor-mediated mobilization.

Authors:  K Lam; A Muselman; R Du; M Yan; S Matsuura; D-E Zhang
Journal:  Blood Cancer J       Date:  2016-03-25       Impact factor: 11.037

9.  Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.

Authors:  Brian A Jonas; Carl Johnson; Dita Gratzinger; Ravindra Majeti
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

10.  Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1.

Authors:  Christine Feld; Peeyush Sahu; Miriam Frech; Florian Finkernagel; Andrea Nist; Thorsten Stiewe; Uta-Maria Bauer; Andreas Neubauer
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.